FGI-106

FGI-106

Systematic (IUPAC) name
1-N,7-N-bis[3-(dimethylamino)propyl]-3,9-dimethylquinolino[8,7-h]quinoline-1,7-diamine
Clinical data
Legal status	Investigational New Drug
Identifiers
CAS Number	501081-38-5
PubChem	CID 432342
ChemSpider	382357
Chemical data
Formula	C28H38N6
Molar mass	458.640
SMILES CN(C)CCCNc(c2ccc14)cc(C)nc2c1ccc3c4nc(C)cc3NCCCN(C)C
InChI InChI=1S/C28H38N6/c1-19-17-25(29-13-7-15-33(3)4)23-11-10-22-21(27(23)31-19)9-12-24-26(18-20(2)32-28(22)24)30-14-8-16-34(5)6/h9-12,17-18H,7-8,13-16H2,1-6H3,(H,29,31)(H,30,32) Key:WJUPENLNVUCETH-UHFFFAOYSA-N

FGI-106 is a broad-spectrum antiviral drug developed as a potential treatment for enveloped RNA viruses, in particular viral hemorrhagic fevers from the bunyavirus, flavivirus and filovirus families. It acts as an inhibitor which blocks viral entry into host cells. In animal tests FGI-106 shows both prophylactic and curative action against a range of deadly viruses for which few existing treatments are available, including the bunyaviruses Hantavirus, Rift Valley fever virus and Crimean-Congo hemorrhagic fever virus, the flavivirus Dengue virus, and the filoviruses Ebola virus and Marburg virus.^[1][2][3][4]

See also

• Brincidofovir
• BCX4430
• Favipiravir
• FGI-103
• FGI-104
• LJ-001
• TKM-Ebola
• ZMapp

References

1. Aman, M. J.; Kinch, M. S.; Warfield, K.; Warren, T.; Yunus, A.; Enterlein, S.; Stavale, E.; Wang, P.; Chang, S.; Tang, Q. (2009). "Development of a broad-spectrum antiviral with activity against Ebola virus". Antiviral Research 83 (3): 245–251. doi:10.1016/j.antiviral.2009.06.001.
2. Kinch (2010). "Development of FGI-106 as a broad-spectrum therapeutic with activity against members of the family Bunyaviridae". Virus Adaptation and Treatment: 9. doi:10.2147/VAAT.S6903.
3. Basu, A.; Li, B.; Mills, D. M.; Panchal, R. G.; Cardinale, S. C.; Butler, M. M.; Peet, N. P.; Majgier-Baranowska, H.; Williams, J. D.; Patel, I.; Moir, D. T.; Bavari, S.; Ray, R.; Farzan, M. R.; Rong, L.; Bowlin, T. L. (2011). "Identification of a Small-Molecule Entry Inhibitor for Filoviruses". Journal of Virology 85 (7): 3106–3119. doi:10.1128/JVI.01456-10.
4. Ippolito, G.; Feldmann, H.; Lanini, S.; Vairo, F.; Di Caro, A.; Capobianchi, M.; Nicastri, E. (2012). "Viral hemorrhagic fevers: Advancing the level of treatment". BMC Medicine 10: 31. doi:10.1186/1741-7015-10-31. PMC 3325866. PMID 22458265.